BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the medical technology company’s stock.

Several other analysts also recently weighed in on the company. Ascendiant Capital Markets decreased their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Benchmark restated a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research note on Monday, August 12th. Finally, Maxim Group downgraded BIOLASE from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 24th.

BIOLASE Stock Performance

Shares of NASDAQ BIOL opened at $0.05 on Tuesday. The firm has a market cap of $1.74 million, a price-to-earnings ratio of 0.00 and a beta of 0.66. The business’s 50-day simple moving average is $0.06 and its 200-day simple moving average is $0.12. BIOLASE has a 52 week low of $0.04 and a 52 week high of $2.26.

BIOLASE (NASDAQ:BIOL) last issued its quarterly earnings data on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. BIOLASE had a negative net margin of 41.65% and a negative return on equity of 1,782.73%. The company had revenue of $11.56 million for the quarter.

Institutional Trading of BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC grew its position in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. 8.79% of the stock is currently owned by hedge funds and other institutional investors.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.